KING Igraine plc

 
TIDMKING 
 
19 August 2022 
 
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO 
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION 
(EU) NO. 596/2014, AS AMENDED ("MAR"). ON THE PUBLICATION OF THIS ANNOUNCEMENT 
VIA A REGULATORY INFORMATION SERVICE ("RIS"), THIS INSIDE INFORMATION IS NOW 
CONSIDERED TO BE IN THE PUBLIC DOMAIN. 
 
                                  Igraine plc 
 
                                  AQSE: KING 
 
                         ("Igraine" or "the Company") 
 
 Investee Update: ARCADIA trial report - Lancet eClinicalMedicine publication 
 
Investee: EML 
 
Igraine plc maintains a 2% Equity Interest in, Excalibur Medicines Ltd ("EML"), 
 
EML has secured exclusive rights to and owns the patents on a drug, AZD1656, 
which is being developed as a potential therapeutic for people with diabetes 
suffering from COVID-19. As there are very few new therapeutics in development 
for COVID-19 and associated virally transmitted diseases (most research is in 
combining existing treatments) this has the potential to be highly attractive 
to big pharma and biotech buyers. 
 
           ARCADIA CLINICAL STUDY REPORT - LANCET eClinicalMedicine 
 
St George Street Capital, a UK-based biomedical charity, and Excalibur 
Medicines Ltd., a biotechnology investment company, are pleased to announce the 
publication in Lancet eClinicalMedicine of our Phase 2 clinical trial, ARCADIA, 
which investigated AZD1656 for people with diabetes hospitalised with COVID19. 
 
Patients in the AZD1656 arm were observed to have lower mortality; 
additionally, AZD1656 was shown to have immunomodulatory capability, as 
predicted. The paper also details our sub-group analysis of patients considered 
to be at higher risk of worse COVID-19 outcomes, either with elevated IL-6 or 
those with low Vitamin D status. 
 
As summarised in the paper: "the evidence presented here suggests that specific 
activation of T-regs might suppress the inappropriate inflammation which is the 
prime cause of tissue damage in autoimmune disease." 
 
St George Street and EML are continuing to have discussions with potential 
partners regarding AZD1656. The full Lancet report can be read here ARCADIA 
study protocol: a phase II, randomised, double-blind, placebo-controlled 
clinical trial to assess the safety and efficacy of AZD1656 in patients with 
diabetes hospitalised with suspected or confirmed COVID-19 | BMJ Open 
 
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00334-0/ 
fulltext 
 
The Directors of the Company, who have issued this RIS announcement after due 
and careful enquiry, accept responsibility for its content. 
 
Enquiries 
 
Company 
 
Steve Winfield (Executive Director) 
 
info@igraineplc.com 
 
Office Line: +44 (0) 20 3778 0755 
 
AQSE Growth Market Corporate Adviser 
 
Peterhouse Capital Limited 
 
Guy Miller / Mark Anwyl 
 
Tel: +44 (0) 207 469 0930 
 
Media inquiries: 
 
Ramsay Smith, Media House International 
 
ramsay@mediahouse.co.uk: +44 (0) 7788414856 
 
 
 
END 
 
 

(END) Dow Jones Newswires

August 19, 2022 03:55 ET (07:55 GMT)

Igraine (AQSE:KING)
Gráfica de Acción Histórica
De Feb 2025 a Mar 2025

Igraine (AQSE:KING)
Gráfica de Acción Histórica
De Mar 2024 a Mar 2025